Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 10,483 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase III Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

NCT01888497
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin, Diphenhydramine citrate, Triazolam, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
4
States / cities
South Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Oct 25, 2026, 8:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Biological · Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
28
States / cities
Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection Prevention
Interventions
Ad26.RSV.preF-based Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • El Dorado, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

NCT00293059
View directory record Official record
Conditions
Metrorrhagia
Interventions
Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
37
States / cities
Lake Havasu City, Arizona • Greenbrae, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

NCT05610280
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases, Atherosclerosis
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

NCT00061880
View directory record Official record
Conditions
Lymphoma
Interventions
forodesine hydrochloride
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 25, 2026, 8:15 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

NCT03281954
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Placebo, Atezolizumab
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
212
States / cities
Mobile, Alabama • Anchorage, Alaska • Jonesboro, Arkansas + 164 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 25, 2026, 8:15 AM EDT
Completed No phase listed Observational

Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo

NCT02192554
View directory record Official record
Conditions
Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Not listed
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Costa Mesa, California • Lakewood, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)

NCT04432376
View directory record Official record
Conditions
Otomycosis
Interventions
miconazole 2% oil, vehicle oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
7 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Chula Vista, California • La Jolla, California • Roseville, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 25, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional

S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx

NCT00003040
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
laser surgery, radiation therapy
Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
12
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 25, 2026, 8:15 AM EDT
Not listed Phase 3 Interventional

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

NCT04762758
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease
Interventions
(RS)-baclofen, naltrexone hydrochloride and D-sorbitol, Placebo
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
16 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Los Angeles, California • Sacramento, California • New Britain, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

BAY81-8973 Pediatric Safety and Efficacy Trial

NCT01311648
View directory record Official record
Conditions
Haemophilia A
Interventions
Recombinant Factor VIII (Kovaltry, BAY81-8973)
Biological
Lead sponsor
Bayer
Industry
Eligibility
0 Years to 12 Years · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer

NCT00002568
View directory record Official record
Conditions
Ovarian Cancer
Interventions
cisplatin, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

NCT00238368
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 25, 2026, 8:15 AM EDT
Recruiting No phase listed Observational

Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer

NCT04775355
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 2Phase 3 Interventional

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

NCT00041925
View directory record Official record
Conditions
Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions
CGT003 (E2F Duplex Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
116
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2005 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

NCT00545168
View directory record Official record
Conditions
Pediculus Capitis Infestation
Interventions
Spinosad, Permethrin 1%
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Ormond Beach, Florida • West Palm Beach, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 25, 2026, 8:15 AM EDT
Active, not recruiting Phase 3 Interventional

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Medi-546, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
33
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 25, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 25, 2026, 8:15 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 25, 2026, 8:15 AM EDT
Recruiting Phase 3 Interventional

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
40
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 8:15 AM EDT